Biotech Values

[DewDiligence]

RAIN IPOs 8.46M* shares @$17.00:

https://www.globenewswire.com/news-release/2021/04/22/2215659/0/en/Rain-Therapeutics-Announces-Pricing-of-Initial-Public-Offering.html

Rain Therapeutics Inc. is a clinical-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology.

Rain’s lead product candidate, RAIN-32 (milademetan, formerly known as DS-3032), is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to RAIN-32, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

*Assuming exercise of underwriter’s option.